Cytotoxic T lymphocytes to Ebola Zaire virus are induced in mice by immunization with liposomes containing lipid A

Vaccine

Volumn 17, Issue 23-24, 1999, Pages 2991-2998

  Rao, Mangala ^a   Matyas, Gary R ^a   Grieder, Franziska ^b   Anderson, Kevin ^c   Jahrling, Peter B ^c   Alving, Carl R ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

CTL; Ebola virus; Liposomes

Indexed keywords

EPITOPE; LIPID A; LIPOSOME;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL STIMULATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EBOLA VIRUS; FEMALE; IMMUNIZATION; INTRAVENOUS DRUG ADMINISTRATION; IRRADIATION; LYMPHOCYTE ACTIVATION; MEMORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; VACCINATION; VIRUS ATTENUATION;

EID: 0033529590     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00170-X     Document Type: Article

References (44)

1. Regnery R.L., Johnson K.M., Kiley M.P. Virion nucleic acid of Ebola virus. J Virol. 36:1980;465-469.
2. Sanchez A., Kiley M.P., Holloway B.P., Auperin D.D. Sequence analysis of the Ebola virus genome: organization, genetic elements and comparison with the genome of Marburg virus. Virus Res. 29:1993;215-220.
3. Gilligan K.J., Geisbert J.B., Jahrling P.B., Anderson K. Assessment of protective immunity conferred by recombinant vaccinia viruses to guinea pigs challenged with Ebola virus. Brown F., Burton D., Doherty P., Mekalanos J., Norrby E. Vaccines. 1997;87-92 Cold Spring Harbor Laboratory Press, Cold Spring Harbor.
4. Yang Z.-Y., Delgado R., Xu L., Todd R.F., Nabel E.G., Sanchez A., Nichol S.T., Nabel G.J. Differential cellular interactions of the secreted and transmembrane Ebola virus glycoproteins: implication for viral pathogenesis. Science. 279:1998;1034-1037.
5. Baron R.C., McCormick J.B., Zubeir O.A. Ebola virus disease in southern Sudan: hospital dissemination and intrafamilial spread. Bull W.H.O. 61:1983;997-1003.
6. Jahrling PB. In: Lennette EHD, Lennette A, Lennette ET, (editors). Diagnostic procedures for viral, rickettsial and chlamydial infections. Washington, DC: American Public Health Association. 1995. p. 213.
7. Johnson K.M., Lange J.V., Webb P.A., Murphy F.A. Isolation and partial characterization of a new virus causing acute hemorrhagic fever in Zaire. Lancet. 1:1977;569-571.
8. Jahrling P.B., Geisbert T.W., Dalgard D.W., Johnson E.D., Ksiazek T.G., Hall W.C., Peters C.J. Preliminary report: isolation of Ebola virus from monkeys imported to USA. Lancet. 335:1990;502-505.
9. Jahrling P.B., Geisbert J., Swearengen J.R., Jaax G.P., Lewis T., Huggins J.W., Schmidt J.J., LeDuc J.W., Peters C.J. Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch Virol Suppl. 11:1996;135-140.
10. Folks T. Ebola takes a punch. Nature Medicine. 4:1998;16-17.
11. Lupton H.W., Lambert R.D., Bumgardner D.L., Moe J.B., Eddy G.A. Inactivated vaccine for Ebola virus efficacious in guinea pig model. Lancet. 2:1980;1294-1295.
12. Townsend A.R., Gotch F.M., Davey J. Cytotoxic T cells recognize fragments of the influenza nucleoprotein. Cell. 42:1985;457-467.
13. Larsen H.S., Russell R.G., Rouse B.T. Recovery from lethal herpes simplex virus type 1 infection is mediated by cytotoxic T lymphocytes. Infect Immun. 41:1983;197-204.
14. Sethi K.K., Ometa Y., Schneweis K.E. Protection of mice from fatal herpes simplex virus type 1 infection by adoptive transfer of cloned virus-specific and H-2-restricted cytotoxic T lymphocytes. J Gen Virol. 64:1983;443-447.
15. Moore M.W., Carbone F.R., Bevan M J. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell. 54:1988;777-785.
16. Deres K., Schild H., Wiesmuller K.H., Jung G., Rammensee H.G. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature. 342:1989;561-564.
17. Martinon F., Gras-Masse H., Boutillon C., Chirat F., Deprez B., Guillet J.G., Gomard E., Tartar A., Levy J.P. Immunization of mice with lipopeptides bypasses the prerequisite for adjuvant: immune response of BALB/c mice to human immunodeficiency virus envelope glycoprotein. J Immunol. 149:1992;3416-3422.
18. Schild H., Norda M., Deres K., Falk K., Rotzschke O., Wiesmuller K.H., Jung G., Rammensee H.G. Fine specificity of cytotoxic T lymphocytes primed in vivo either with virus or synthetic lipopeptide vaccine or primed in vitro with peptide. J Exp Med. 174:1991;1665-1668.
19. Harding C.V., Song R. Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules. J Immunol. 153:1994;4925-4933.
20. Kovacsovics-Bankowski M., Rock K.L. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science. 267:1995;243-246.
21. Alving C.R., Koulchin V., Glenn G.M., Rao M. Liposomes as carriers of peptide antigens: induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides. Immunol Rev. 145:1995;5-31.
22. Lopes L.M., Chain B.M. Liposome-mediated delivery stimulates a class I-restricted cytotoxic T cell response to soluble antigen. Eur J Immunol. 22:1992;287-290.
23. Reddy R., Zhou F., Nair S., Huang L., Rouse B.T. In vivo cytotoxic T lymphocyte induction with soluble proteins administered in liposomes. J Immunol. 148:1992;1585-1589.
24. White K., Krzych U., Gordon D.M., Porter T.R., Richards R.L., Alving C.R., Deal C.D., Hollingdale M., Silverman C., Sylvester D.R., Ballou W.R., Gross M. Induction of cytolytic and antibody responses using Plasmodium falciparum repeatless circum-sporozoite protein encapsulated in liposomes. Vaccine. 11:1993;1341-1346.
25. White W.I., Cassatt D.R., Madsen J., Burke S.J., Woods R.M., Wassef N.M., Alving C.R., Koenig S. Antibody and cytotoxic T-lymphocyte responses to a single liposome-associated peptide antigen. Vaccine. 13:1995;1111-1122.
26. Rao M., Rothwell S.W., Wassef N.M., Pagano R.E., Alving C.R. Visualization of peptides derived from liposome-encapsulated proteins in the trans-Golgi area of macrophages. Immunol Lett. 59:1997;99-105.
27. Rao M., Alving C.R. Class I presentation of liposomal antigens. Lasic D.D., Papahadjopoulos D. Medical applications of liposomes. 1998;15-24 Elsevier, New York.
28. Falk K., Rotzschke O., Deres K., Metzger J., Jung G., Rammensee H.G. Identification of naturally processed viral nonapeptides allows their quantification in infected cells and suggests an allele-specific T cell epitope forecast. J Exp Med. 174:1991;425-434.
29. Rammensee H.G., Falk K., Rotzchke O. Peptides naturally presented by MHC class I molecules. Ann Rev Immunol. 11:1993;213-214.
30. d-restricted antigenic peptides share a simple binding motif. J Exp Med. 174:1991;603-612.
31. Alving CR, Shichijo S, Mattsby-Baltzer, I, Richards RL, Wassef NM. Preparation and use of liposomes in immunological studies. In: Gregoriadis G, (editor). Liposome technology, Vol. 3. Boca Raton, FL: CRC Press, Inc. 1993. p. 317-343.
32. Wassef N.M., Alving C.R., Richards R.L. Liposomes as carriers for vaccines. Immunometh. 4:1994;217-222.
33. Elliott L.H., McCormick J.B., Johnson K.M. Inactivation of Lassa, Marburg, and Ebola viruses by gamma irradiation. J Clin Microbiol. 16:1982;704-708.
34. Chain B.M., Sealy L., Katz D.R., Brinks M. Antigen processing and presentation. Delves P.J. Cellular immunology LabFax. 1994;177-194 Academic Press, New York.
35. Reddehase M.J., Keil G.M., Koszinowski U.H. The cytolytic T lymphocyte response to the murine cytomegalovirus. II. Detection of virus replication stage-specific antigens by separate populations of in vivo active cytolytic T lymphocyte precursors. Eur J Immunol. 14:1994;56-61.
36. Liu T., Zhou X., Orvell C., Lederer E., Ljunggren H.-G., Jondal M. Heat-inactivated Sendai virus can enter multiple MHC class I processing pathways and generate cytotoxic T lymphocyte responses in vivo. J Immunol. 154:1995;3147-3155.
37. Alving C.R., Wassef N.M. Cytotoxic T lymphocytes induced by liposomal antigens: mechanisms of immunologic presentation. AIDS Res Human Retrovirol. 10:(Suppl. 1):1994;S91-S94.
38. Jondal M., Schirmbeck R., Reimann J. MHC class I restricted CTL responses to exogenous antigens. Immunity. 5:1996;295-302.
39. Zhou F., Huang L. Monophosphoryl lipid A enhances specific CTL induction by a soluble protein antigen entrapped in liposomes. Vaccines. 11:1993;1139-1144.
40. Verma J.N., Rao M., Amselem S., Krzych U., Alving C.R., Green S.J., Wassef N.M. Adjuvant effects of liposomes containing lipid A: enhancement of liposomal antigen presentation and recruitment of macrophages. Infect Immun. 60:1992;2438-2444.
41. Volchkov V.E., Blinov V.M., Netesov S.V. The envelope glycoprotein of Ebola virus contains an immunosuppressive-like domain similar to oncogenic retroviruses. FEBS Lett. 305:1992;181-184.
42. Xu L., Sanchez A., Yang Z.Y., Zaki S.R., Nabel E G., Nichol S.T., Nabel G J. Immunization for Ebola virus infection. Nat Med. 4:1998;37-42.
43. Vanderzanden L., Bray M., Fuller D., Roberts T., Custer D., Spik K., Jahrling P., Huggins J., Schmaljohn A., Schmaljohn C. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology. 246:1998;134-144.
44. Bray M., Davis K., Geisbert T., Schmaljohn C., Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis. 178:1998;651-661.